Wall Street analysts forecast that Veru Inc (NASDAQ:VERU) will announce sales of $9.26 million for the current quarter, Zacks reports. Three analysts have provided estimates for Veru’s earnings, with the highest sales estimate coming in at $11.19 million and the lowest estimate coming in at $8.20 million. Veru posted sales of $5.20 million in the same quarter last year, which suggests a positive year-over-year growth rate of 78.1%. The company is expected to report its next quarterly earnings results on Thursday, December 12th.
According to Zacks, analysts expect that Veru will report full-year sales of $32.35 million for the current financial year, with estimates ranging from $31.30 million to $34.26 million. For the next year, analysts forecast that the firm will post sales of $34.96 million, with estimates ranging from $33.90 million to $35.97 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Veru.
Veru (NASDAQ:VERU) last released its earnings results on Thursday, August 8th. The company reported ($0.04) EPS for the quarter, hitting analysts’ consensus estimates of ($0.04). The company had revenue of $9.73 million during the quarter, compared to analysts’ expectations of $8.11 million. Veru had a negative net margin of 59.68% and a negative return on equity of 50.14%.
In other Veru news, CFO Michele Greco acquired 20,000 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was acquired at an average cost of $1.84 per share, for a total transaction of $36,800.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Mitchell Shuster Steiner sold 30,000 shares of Veru stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $1.93, for a total transaction of $57,900.00. Over the last quarter, insiders purchased 47,000 shares of company stock valued at $89,040 and sold 80,000 shares valued at $170,700. 29.50% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Perceptive Advisors LLC lifted its stake in Veru by 1.4% during the 2nd quarter. Perceptive Advisors LLC now owns 1,445,000 shares of the company’s stock valued at $3,078,000 after acquiring an additional 20,000 shares during the period. Renaissance Technologies LLC lifted its stake in Veru by 183.1% during the 2nd quarter. Renaissance Technologies LLC now owns 262,160 shares of the company’s stock valued at $558,000 after acquiring an additional 169,550 shares during the period. BlackRock Inc. lifted its stake in Veru by 65.4% during the 2nd quarter. BlackRock Inc. now owns 228,934 shares of the company’s stock valued at $487,000 after acquiring an additional 90,530 shares during the period. Finally, Wedge Capital Management L L P NC acquired a new stake in Veru during the 2nd quarter valued at approximately $394,000. Institutional investors and hedge funds own 8.83% of the company’s stock.
VERU stock traded up $0.06 during trading on Friday, reaching $2.09. The company had a trading volume of 120,333 shares, compared to its average volume of 169,727. The firm has a 50-day simple moving average of $1.96 and a 200-day simple moving average of $1.83. The company has a market cap of $133.98 million, a price-to-earnings ratio of -5.36 and a beta of 0.44. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.20 and a current ratio of 1.47. Veru has a twelve month low of $1.18 and a twelve month high of $2.49.
Veru Company Profile
Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.
See Also: What is an inverted yield curve?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.